Testing tolerance of BI 3804379 in healthy people and MASH patients
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- If you are generally healthy, your body mass index (BMI) must be between 18.5 and 30.
- If you have MASH, you must have advanced liver scarring (fibrosis) due to MASH.
- You cannot have uncontrolled diabetes, severe heart or kidney problems, or recent significant weight loss.
- You must not have taken any other experimental drugs in the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how safe and tolerable different doses of the study drug BI 3814916 are in healthy adults. It helps find the right dose for future studies.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.